Creative Medical Technology Holdings (CELZ) Amortization - Intangibles (2016 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Amortization - Intangibles of $28855.0 for Q1 2026, down 5.63% year-over-year from $30577.0 in Q1 2025, and down 6.77% quarter-over-quarter from $30949.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Amortization - Intangibles (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Amortization - Intangibles for 11 consecutive years, with $28855.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles fell 5.63% year-over-year to $28855.0; the TTM figure through Mar 2026 stood at $121605.0 (up 8.81% YoY), while the FY2025 annual figure was $123327.0, up 11.66% from the prior year.
- Amortization - Intangibles slipped to $28855.0 in Q1 2026 per CELZ's latest filing, from $30949.0 in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $31059.0 in Q3 2025 and bottomed at $22639.0 in Q4 2024.
- Historically, Amortization - Intangibles has averaged $26429.5 across 5 years, with a median of $25521.0 in 2023.
- Annual changes were most pronounced in 2024 — Amortization - Intangibles dropped 11.29% — and 2025, when it jumped 36.71%.
- Creative Medical Technology Holdings' Amortization - Intangibles stood at $23021.0 in 2022, then rose by 10.86% to $25521.0 in 2023, then decreased by 11.29% to $22639.0 in 2024, then soared by 36.71% to $30949.0 in 2025, then retreated by 6.77% to $28855.0 in 2026.
- Business Quant data shows CELZ's Amortization - Intangibles at $28855.0 in Q1 2026, $30949.0 in Q4 2025, and $31059.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22,918.00 |
| Mar 31, 2026 | 28,855.00 |
| Dec 31, 2025 | 30,949.00 |
| Sep 30, 2025 | 31,059.00 |
| Jun 30, 2025 | 30,742.00 |
| Mar 31, 2025 | 30,577.00 |
| Dec 31, 2024 | 22,639.00 |
| Sep 30, 2024 | 29,271.00 |
| Jun 30, 2024 | 29,271.00 |
| Mar 31, 2024 | 29,271.00 |
| Dec 31, 2023 | 25,521.00 |
| Sep 30, 2023 | 23,021.00 |
| Jun 30, 2023 | 23,021.00 |
| Mar 31, 2023 | 23,021.00 |
| Dec 31, 2022 | 23,021.00 |
| Sep 30, 2022 | 23,021.00 |
| Jun 30, 2022 | 23,021.00 |
| Mar 31, 2022 | 23,021.00 |
| Dec 31, 2021 | 23,021.00 |
| Sep 30, 2021 | 23,021.00 |